<DOC>
	<DOCNO>NCT00189839</DOCNO>
	<brief_summary>The purpose study evaluate compare efficacy safety triple modify release tacrolimus FK506E ( MR4 ) / MMF / steroid regimen triple standard tacrolimus FK506 / MMF / steroid regimen patient undergo kidney transplantation . It shall demonstrate FK506E ( MR4 ) non-inferior FK506 regard primary endpoint .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy FK506E ( MR4 ) Patients Undergoing Primary Kidney Transplantation</brief_title>
	<detailed_description>A multicentre , 1:1 randomise , double blind , double dummy , two arm parallel group phase III study compare triple modified release tacrolimus FK506E ( MR4 ) / MMF / steroid regimen triple standard tacrolimus FK506 / MMF / steroid regimen .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients receive kidney transplant cadaveric donor living non HLA identical donor 5 65 year age compatible ABO blood type . Patients end stage kidney disease suitable candidate primary renal transplantation retransplantation ( unless graft lose immunological reason within 12 month ) . Patients receive previously receive organ transplant kidney . Patients high immunological risk , define panel reactive antibody ( PRA ) grade &gt; 50 % previous 6 month and/or previous graft survival le 12 month due immunological reason . Cold ischaemia time donor kidney &gt; 30 hour .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Kidney transplantation</keyword>
	<keyword>Transplantation , kidney</keyword>
	<keyword>Renal Transplantation</keyword>
	<keyword>Transplantation , renal</keyword>
</DOC>